The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
Scope
This report gives an important monthly update on the pharmaceutical outsourcing industry, based on analysis from the analyst's experts and our databases covering deals, companies, drugs, financials, news, clinical trials, and more. This report is required reading for:- CMO executives and strategic decision-makers: to improve understanding of the CMO industry and provide a critical input for strategic planning efforts.
- Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.
- Investors, advisors, and consultants: they can gain a deeper understanding of the CMO market and important insights for identifying potential investment targets.
Reasons to Buy
- Understand current trends and equip yourself with forward-thinking strategies to navigate challenges and capitalise on emerging trends driving the pharmaceutical manufacturing industry. Use our radar to identify developments and innovations with high impact.
- Discover the latest opportunities and threats in the contract manufacturing industry, based on clinical trials and regulatory decisions.
- Learn about the past quarter’s M&A and financing deals in the manufacturing space.
- Identify the latest contract service agreements.
- Develop your competitor or market intelligence by reading about inspection outcomes and facility investments.
- Stay ahead of disruption with updates on supply chain obstacles and new regulations.
Table of Contents
1 Industry Trends
2 Industry Analysis
3 Value Chain
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aenova Holding GmbH
- AGC Biologics Inc
- Almac Group Ltd
- Amgen Europe BV
- Anapharm Bioanalytics
- AstraZeneca Plc
- Averoa SAS
- Bayer Plc
- Bend Bioscience LLC
- BeiGene Ltd
- BioSpring GmbH
- Biosynth GmbH
- Bristol-Myers Squibb Co
- Bryllan LLC
- Carbogen Amcis AG
- Catalent
- Cell and Gene Therapy Catapult
- Cellipont Bioservices
- Charles River Laboratories International Inc
- Chime Biologics Ltd
- CEM Analytical Services Ltd
- Delpharm SAS
- Dewcell Biotherapeutics Co Ltd
- Dottikon Exclusive Synthesis AG
- Emergent BioSolutions Inc
- Exela Pharma Sciences LLC
- Farmhispania SA
- Fareva SA
- Flamma SpA
- Glenmark Pharmaceuticals Ltd
- GC Biopharma Corp
- Hikma Pharmaceuticals Plc
- Hikma Pharmaceuticals USA Inc
- Humanigen Inc
- IBERFAR Industria Farmaceutica SA
- Incyte Corp
- Jazz Pharmaceuticals Plc
- Kaneka Eurogentec SA
- Kindeva Drug Delivery LP
- Laboratorios Farmaceuticos Rovi SA
- Lifecore Biomedical LLC
- Lotte Biologics Co Ltd
- Lonza
- Mabxience Holding SL
- Merck & Co Inc
- Moderna Inc
- National Resilience Inc
- Nelson Laboratories LLC
- Nippon Shokubai Co Ltd
- NUVISAN Pharma Holding GmbH
- Organon & Co
- Patheon
- PCI Pharma Services
- Piramal Pharma Solutions Inc
- ProBio Inc
- Recipharm AB
- Rechon Life Science AB
- ROVI Pharma Industrial Services SA
- Samsung Biologics Co Ltd
- Sanofi-Aventis US LLC
- Sepha Ltd
- Sever Pharma Solutions AB
- Simtra US LLC
- SK Pharmteco Inc
- Sumitomo Chemical Co Ltd
- Thermo Fisher Scientific Inc
- Time-Cap Labs Inc
- VaxCell Biotherapeutics Co Ltd
- Vetter Pharma-Fertigung GmbH & Co KG
- WuXi Biologics Co Ltd
- WuXi XDC Cayman Inc
- Zambon Co SpA
- Zentiva Group AS
